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Abstract 
Background and aim: Hypertensive pregnancy disorders are associated with subsequent 
cardiovascular disease (CVD), but the extent to which this association is explained by shared risk 
factors is unknown. We aimed to evaluate whether hypertensive pregnancy disorder in first 
pregnancy is associated with increased subsequent risk of maternal CVD after adjustment for 
established CVD risk factors measured after pregnancy. Methods and results: A total of 20,075 
women with a first delivery registered in the Medical Birth Registry of Norway (1980–2003) 
participated in Cohort of Norway (CONOR) health surveys a mean (standard deviation) of 10.7 (5.5) 
years after delivery. They were then followed (median 11.4 years) for an incident fatal or nonfatal 
CVD event through linkage to the Cardiovascular Disease in Norway (CVDNOR) database and the 
Norwegian Cause of Death Registry. Hypertensive pregnancy disorders were associated with an 
increased risk of CVD [Hazard ratio (HR) 2.3; 95% confidence interval (CI) 1.9–2.8], which remained 
significant after adjustment for established CVD risk factors including body mass index, smoking, 
hypertension, diabetes, serum glucose and lipid levels (HR 1.5; 95% CI 1.2–1.8). The population 
attributable fraction of CVD due to hypertensive pregnancy disorder was 4.3% (95% CI 1.9–6.6) after 
multivariable adjustment. Conclusion: The association between hypertensive pregnancy disorders 
and CVD risk was mediated in part by related CVD risk factors measured 10 years following delivery. 
These results underline the importance of postpregnancy follow-up of women with hypertensive 





Hypertensive disorders (preeclampsia and gestational hypertension) affect 5-10% of 
pregnancies worldwide [1] and contribute significantly to the global burden of maternal and 
perinatal morbidity and mortality [2]. Studies have found that hypertensive pregnancy 
disorders associate with increased risk of short- and long-term maternal cardiovascular 
disease (CVD) [3-8]. We have recently found an increased risk for CVD associated with 
preeclampsia [9] and gestational hypertension [10], with the risk tending to be higher when 
the hypertensive pregnancy disorder occurred simultaneously with a small for gestational age 
(SGA) infant and/or preterm delivery. Whether pregnancy complications unmask an already 
existing CVD risk or whether the hypertensive pregnancy disorder is causally related to 
maternal risk of CVD remains uncertain. The first hypothesis is supported by the fact that 
established risk factors such age, smoking, elevated body mass index (BMI), low density 
lipoprotein (LDL) cholesterol, diabetes mellitus and a family history of coronary heart disease 
(CHD) are shared between hypertensive pregnancy disorders and CVD [11, 12], and that 
endothelial dysfunction is central to the development of both disorders [13, 14]. Alternatively, 
the proatherogenic stress of pregnancy could contribute to an arterial wall inflammation that is 
not resolved after delivery [15], and may lead to further increased risk of CVD. The two 
hypotheses are not mutually exclusive. 
Although the overall CVD mortality rates have declined over the past decades in 
western countries [16], in the United States, mortality from coronary heart disease has 
plateaued among young women <55 years since the year 2000 [17] and in Norway, the overall 
falling incidence and recurrences of acute myocardial infarction over the past decades do not 
encompass younger women [18, 19]. 
 In general, 80% of CVD development may be explained by established risk factors 




women [23, 24]. While an association between hypertensive pregnancy disorders and later 
CVD has been repeatedly reported, the possible impact of established risk factors on this 
association is not known. An attenuation of risk estimates is observed when adjusting for 
established CVD risk factors, but hypertensive pregnancy disorders seem to remain persistent 
and significant predictors of later CVD [5, 6, 25-27]. The existing studies are limited by 
missing or inadequate data risk factors (e.g. lipids, blood pressure, height and weight) [5, 25-
27], parity [6], gestational hypertension [6, 26] and by survival bias [6]. Furthermore, Cain et 
al. (2016) found higher risk of CVD after preeclampsia, but not after gestational hypertension, 
when accounting for established risk factors [5].  
This study aimed to explore the extent to which established CVD risk factors explain 
the association between hypertensive pregnancy disorders in first pregnancy and subsequent 







By use of the national identification number unique to each Norwegian resident, we linked 
data from the Medical Birth Registry of Norway (MBRN) [28] to Cohort of Norway 
(CONOR) health surveys [29], the Cardiovascular Disease in Norway 1994–2009 
(CVDNOR) database [30,31], and the Norwegian Cause of Death Registry (1980-2009) [32]. 
Further linkages to Statistics Norway and the National Registry provided us with information 
on educational level and date of emigration. A detailed description of the registries can be 
found in supplemental material.  
 
 Ethical considerations 
The study was approved by The Regional Committee for Medical and Health Research Ethics 
(2014/1047). All CONOR participants signed a written informed consent for research and 
linkage of health registries.  
 
Study population 
A total of 23,369 women (age 16-49 with parity ≤5) registered with a first delivery in the 
MBRN (1980 through 2003) subsequently participated in one or more regional CONOR 
surveys between 1994 and 2003. For women who had participated in more than one health 
survey after the first pregnancy (n=510), information from the last survey was used. Date of 
CONOR participation served as baseline for the follow-up evaluation of CVD events and we 
excluded women who were pregnant at that time (n=825). Women with a recorded diagnosis 
of CVD (ICD-9 codes 390-459; ICD–10 codes I00-I99, except 455/I84 (hemorrhoids)) in the 
MBRN/CVDNOR before baseline (CONOR) were excluded (n=469). Using information from 




weeks of gestation and women with infants born with a weight-for-gestational age and sex z-
score more extreme than -4/+4 (n=63); those with multiple-birth pregnancies (n=277); and 
missing information on SGA and/or preterm delivery (defined below) (n=1,415). In addition, 
we excluded women with missing CONOR information on age, blood pressure, total serum 
cholesterol (total- C), high-density lipoprotein cholesterol (HDL-C), triglycerides, daily 
smoking, BMI or a family history of MI (n=207). Lastly, women with missing information on 
education were excluded (n=38). The final cohort included 20,075 women (Supplementary 
Figure 1).  Sensitivity analyses showed only minimal differences in characteristics of 
excluded women according to exposure status. 
 
Exposures 
The main exposures for the current study was gestational hypertension or preeclampsia in the 
first pregnancy. Gestational hypertension was defined as hypertension identified after 20 
weeks of gestation (systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg, or an increase 
>15 mm Hg from blood pressure measured before gestational week 20). According to the 
definition in the MBRN, the preeclampsia diagnosis required the additional presence of 
proteinuria (≥0.3 g in 24 hour urine or ≥1 point increase on dip-stick), and also included 
eclampsia and the HELLP syndrome. SGA offspring was defined as fetal growth below the 
10th  percentile based on Norwegian sex-specific birthweight curves [33] and preterm delivery 
was defined as delivery before 37 weeks of gestation. 
 
Endpoints 
The primary endpoint was the first episode of CVD (ICD-9 codes 390-459; ICD-10 codes 
I00-I99; either non-fatal or fatal (except 455 and I84)) identified through CVDNOR or the 




401-405; ICD-10 I10-I15) (Supplementary Table 1), accounting for one third of the cases. 
Secondary endpoints included coronary heart disease (CHD) (ICD-9 410-414; ICD-10 I20-
25), and the combined endpoint of acute myocardial infarction (AMI) or acute cerebral stroke. 
The endpoint AMI or acute cerebral stroke was defined as the first occurrence of 
hospitalization with AMI (ICD-9 410; ICD-10 I21-22) or death from CHD (ICD-9 410-414; 
ICD-10 I20-25), and hospitalization or death with acute cerebral stroke (ICD-9 43; ICD-10 
I60-61, I63-64 (except I63.6)).  
 
Statistical analyses 
All potential CVD risk factors available were evaluated for statistical associations with the 
exposure (hypertensive disorders of pregnancy) and the outcomes (CVD). From the MBRN 
we used mother’s age at first delivery. From CONOR we first evaluated the following 
parameters separately: age at baseline (CONOR), blood pressure reading in the hypertensive 
range [hereafter referred to as hypertension [defined as systolic blood pressure ≥140 and/or 
diastolic blood pressure ≥90 mm Hg and/or use of antihypertensive drugs (yes or no)], 
diabetes mellitus (yes (type 1, type 2, unspecified) or no), daily smoking (yes or no), family 
history of MI before the age of 60 (yes or no), low HDL-C ( yes (≤1.3 mmol/L) or no)), total-
C (mmol/L), triglycerides (mmol/L), glucose (mmol/L) alcohol consumption (never/seldom, 
monthly, weekly), vigorous physical activity (hours per week: none, less than 1, 1-2, 3 or 
more) and BMI (kg/m2) (model 1). Information on serum glucose, alcohol consumption and 
physical vigorous activity was missing for 13.1%, 4.7% and 8.7% of the women, respectively, 
and were therefore not included in the main analyses. Secondly, risk associations were 
explored using Cox proportional hazard regression and results were reported as hazard ratios 
(HRs) and corresponding 95% confidence intervals (CIs). The proportional hazards 




Follow-up time was calculated as time from participation in CONOR until hospital admission, 
death, emigration or December 31, 2009 (whichever occurred first).  
Hypertensive pregnancy disorders were stratified into gestational hypertension and 
preeclampsia and term and preterm deliveries to study potential subgroup differences. We 
also tested for significant interactions between hypertensive pregnancy disorders and each of 
the CVD risk factors. No interactions were significant and therefore not included in further 
analyses. 
In additional analyses, we excluded women who had their first delivery within six 
months before CONOR and women who had a subsequent delivery within six months before 
or nine months after CONOR since these women may have risk factor alterations due to 
pregnancy itself.  Further, we also included all established CVD risk factors in the fully 
adjusted model independent of missing values to study potential changes in estimates; women 
with missing values on one or more covariates were excluded from these analyses (complete 
case analysis).  
The level of significance was defined as P <0.05 in all analyses. Stata 15 and R were 
used in the analyses. 
 
Risk prediction 
We investigated the potential value of including hypertensive pregnancy disorders in CVD 
risk prediction by comparing two models. Model 1 included age at baseline, age at first 
delivery, hypertension, diabetes mellitus, daily smoking, family history of MI before the age 
of 60, low HDL-C, total-C, triglycerides and BMI. Model 2 additionally included 
hypertensive pregnancy disorder. All continuous variables were mean centered to get a 
reasonable baseline level for estimation of baseline survival. The predicted 10-year risk was 




1 − ?̂?𝑆(10)exp (𝑍𝑍∗𝛽𝛽) 
where ?̂?𝑆(10) is the predicted baseline survival at 10 years of follow-up, Z is the vector of 
covariates and β is the vector of regression coefficients. 
The models` ability to distinguish between those who do and do not develop the 
disease of interest (discrimination) was evaluated with Harrell’s C-statistics [34] obtained 
using the STATA package somersd. Akaike information criterion (AIC) and Bayes 
information criterion (BIC) were reported as measures of improvement of model fit. Studies 
have shown that the C-statistic is insensitive in evaluating risk prediction models [35]. Thus, 
we calculated net reclassification improvement (NRI) and integrated discrimination 
improvement (IDI) using the “survIDINRI” package in R [36-38]. Only women with the 
possibility of at least 10 years follow-up for CVD were included in the risk prediction 
analyzes (n=12,389, events=688).  
 
Attributable risk 
The attributable fraction can be interpreted as the burden of CVD attributable to hypertensive 
pregnancy disorders. The attributable fraction was calculated by the STATA package punafcc 







Characteristics of the study population 
Baseline demographic characteristics stratified by hypertensive pregnancy disorder are 
presented in Table 1. The mean (standard deviation (SD)) for the time between first delivery 
and participating in CONOR was 10.7 (5.5) years. Mean (SD) age of women at first delivery 
was 26.0 (4.6) years. A total of 1246 (6.2%) women were diagnosed with a hypertensive 
pregnancy disorder in their first pregnancy. Women with a hypertensive pregnancy disorder 
had a greater prevalence of preterm (P <0.001), SGA (P <0.001) and stillbirth deliveries (P 
=0.001) compared to women without a hypertensive pregnancy disorder. In the subsequent 
CONOR health survey, women with a hypertensive pregnancy disorder had higher prevalence 
of diabetes mellitus and systolic and diastolic blood pressure, BMI, total-C and triglycerides, 
but lower HDL-C, as well as less smoking and alcohol consumption compared to women with 
no hypertensive pregnancy disorder (all P <0.001).  
Figure 1 presents age-adjusted HR`s for CVD events for each CVD risk factor 
examined. Vigorous physical activity reported at CONOR baseline was associated with a 
decreased risk of CVD (HR 0.8; 95% CI 0.7-0.9).  All other factors analyzed predicted an 
increased risk of CVD; e.g. women with hypertension and women with BMI ≥30 had HR`s of 
3.5 (95% CI 3.1-4.0) and 3.2 (2.7-3.7), respectively, for the risk of CVD.  
 
The importance of CVD risk factors in the association between hypertensive pregnancy 
disorder and later CVD 
Associations of hypertensive pregnancy disorder with subsequent maternal CVD are 
presented in Table 2. The median duration of follow-up from CONOR participation was 11.4 
years (Q1-Q3: 8.7-13.6). In the unadjusted analyses, hypertensive pregnancy disorder in first 




adjustment for non-modifiable and modifiable risk factors, the HR was partially attenuated 
but remained an independent risk factor for maternal CVD (HR 1.5; 95% CI 1.2-1.8). 
Corresponding HR for the combined endpoint AMI/acute cerebral stroke was 1.8 (95 % CI 
1.1-2.9) and for CHD it was 1.5 (95% CI 0.9-2.6). These associations were evident for both 
preeclampsia and gestational hypertension (Table 2). In analyses also adjusting for non-
fasting serum glucose, vigorous physical activity and alcohol consumption, comparable 
results were found (data not shown).  
Women with hypertensive pregnancy disorder combined with preterm delivery had 
increased risk of CVD relative to women without hypertensive pregnancy disorder and term 
delivery; HR 1.9 (95% CI 1.3-2.9) for hypertensive pregnancy disorder, HR 3.6 (95% CI 1.7-
7.6) for gestational hypertension and HR 1.6 (95% CI 1.0-2.7) for preeclampsia 
(Supplementary Table 2). 
In additional analyses where we excluded women with deliveries around CONOR 
participation (six months before - nine months after) no notable changes in risk estimates 
were found (data not shown).  
 
The value of including hypertensive pregnancy disorders in risk prediction 
Based on established CVD risk factors registered at baseline (CONOR) (model 1), women 
with a history of hypertensive pregnancy disorder had a significantly higher predicted 10-year 
mean absolute risk of CVD compared to women with no hypertensive pregnancy disorder 
(0.06% vs 0.04%, P < 0.001). The 10-year risk of CVD for women with a history of 
hypertensive pregnancy disorder was further increased when hypertensive pregnancy disorder 
was included in the 10-year risk prediction model (model 2); 0.09% vs. 0.04%, P <0.001 (data 




Table 3 shows that the predictive value of the survival model increased from 0.69 to 
0.70 when hypertensive pregnancy disorders was included. Both AIC and BIC decreased in 
model 2, indicating an improvement of model fit. NRI and IDI showed no significant 
improvement in the risk prediction model by including hypertensive pregnancy disorder in the 
model.  
 
Population attributable risk 
A total of 7.3% (95% CI 5.1-9.5) of the risk of CVD could be attributed to hypertensive 
pregnancy disorder that occurred an average of 21.9 years earlier. After adjustment for CVD 
risk factors, measured an average of 10.7 years after delivery, the attributable fraction 







After accounting for a number of established modifiable and non-modifiable CVD risk factors 
assessed on average 10 years after pregnancy, a 50% increased risk of maternal CVD after 
hypertensive pregnancy disorder in the woman`s first pregnancy persisted. This suggests that 
the association between the disorders is a result of both shared CVD risk factors and 
pregnancy specific components.  
Hypertensive pregnancy disorder and risk of CVD 
This study identified a strong and persistent risk of CVD after hypertensive pregnancy 
disorders when accounting for established CVD risk factors. Similar associations were found 
for CHD and the combined endpoint AMI/stroke. 
Only one other large cohort study [6] with access to data on blood measures (i.e. 
lipids) and physical examinations (i.e. blood pressure, height and weight (BMI)) have 
identified an impact of hypertensive pregnancy disorders on the risk of future hypertension 
and CVD after adjustment for such parameters, but with somewhat smaller risk estimates. Ray 
et al. 2005 found an increased risk of CVD subsequent to experiencing maternal placental 
syndrome after controlling for CVD risk factors measured after the index delivery [25]. Cain 
et al. 2016 found similar overall results, but the risk of CVD following gestational 
hypertension did not remain significant when accounting for risk factors [5]. This is in 
contrast to our study where an increased risk of future CVD was found for both preeclampsia 
and gestational hypertension after adjustment. Timpka et al. 2017 and Egeland et al. 2018 
reported a higher risk of chronic hypertension after hypertensive pregnancy after accounting 
for several CVD risk factors [26, 27]. In the latter study, the association remained in a 
sensitivity analysis restricted to women with a normal pre-pregnancy BMI (kg/m2) [27]. 
This study contributes important knowledge by showing an independent association 




effects of several established CVD risk factors. Vascular damage associated with hypertensive 
pregnancy disorders is suggested as a mechanism for increasing women’s susceptibility to 
CVD later in life [40]. A link between pregnancy-related complications and CVD risk is 
biologically plausible and supported by the profound effects of pregnancy on the maternal 
cardio-metabolic system [41]. Our uncovering of a dependent and independent risk factor 
component in the association between hypertensive pregnancy disorder and later CVD, is 
suggestive that the underlying aetiology probably is a combination of both shared 
predispositions (familial/genetic and lifestyle) and a direct causal connection between the 
consequences of hypertensive pregnancy disorders and CVD [14, 42].   
 
The value of including hypertensive pregnancy disorders in risk prediction 
The negligible improvement of the 10-year risk prediction model after including hypertensive 
pregnancy disorder as a variable may be partly explained by the relatively short follow-up 
time in this study and the women`s young age. Women in the age group included here have a 
low absolute risk of CVD and few women met the 5 or 10% criteria that are recommended for 
intervention for prevention of CVD. Lower thresholds for interventions in young women and 
men are recommended since CVD risk factors over many years may cause irreversible 
vascular damage [43]. A downside with the established risk prediction models is that new 
variables need to be strongly related to the outcome in order to show statistically significant 
improvement [44, 45]. NRI and IDI are widely used methods based on risk stratification, but 
the translation into clinical practice is questioned [46], and we found no improvement when 
incorporating hypertensive pregnancy disorder in the 10-year risk prediction model.  
We have only identified one previous study who have investigated the predictive value 
of incorporating hypertensive pregnancy disorders into a CVD risk prediction model [47?], 




reclassification. This study was limited by self-reported information on hypertension in 
pregnancy, SBP and the use of predicted, rather than measured, total and HDL cholesterol 
levels.  
Altogether, our findings substantiate larger studies with longer follow-up to determine 
whether hypertensive pregnancy disorders could be a valuable addition to maternal CVD 
prediction scores. Monitoring of women with hypertensive pregnancy disorders is needed as 
they are at higher risk for future CVD. These women should be considered for lifestyle 
rehabilitation aiming at reducing smoking and overweight and improving diet and physical 
activity, and, when indicated, targeted for pharmacological treatment of important mediators, 
such as hypertension and diabetes mellitus.  
 
Population attributable fraction 
About 4.3% of the cardiovascular events, occurring an average of 21.9 years after delivery, 
could be attributed to a history of hypertensive pregnancy disorder after adjusting for risk 
factors measured an average of 10.7 years after delivery. In contrast, a recent Norwegian 
study found that 25.3% of pharmacologically treated hypertension within 10 years of delivery 
was attributed to preeclampsia/gestational hypertension after adjusting for 10 important pre-
pregnancy and 6-months post-partum covariates [27]. The sizable differences in the 
attributable fractions between the current and aforementioned study, likely relate to the length 
of follow-up and the differences in the outcomes assessed. Successful identification and 
treatment of hypertension, a major determinant of CVD and a key mediator between 
hypertensive pregnancy disorders and subsequent CVD, would be expected to result in a low 
attributable fraction percentage associated with hypertensive pregnancy disorders in the 




pregnancy disorders could identify women at risk not identifiable through established CVD 
risk factors.  
 
Strengths and limitations 
The major strengths of our study are the large national cohort with follow-up of incident non-
fatal and fatal CVD. We investigated women in a relatively homogeneous low-risk population 
with low loss to follow-up (<5%), and detailed information on a large number of shared risk 
factors for hypertensive pregnancy disorders and CVD was available. However, several 
limitations need to be addressed. Our data are based on a single measurement of risk factors 
after the woman’s first delivery, and cannot account for changes in risk factors over time. 
Information on diet, genetic, and other risk factors were not available. Residual confounding 
may also have occurred due to inappropriate or imprecise measurements of the CVD risk 
factors. The diagnostic validity for preeclampsia in the MBRN is high [47], but gestational 
hypertension may be less reliable due to underreporting of the less severe cases [48] and 
misdiagnosed chronic hypertension [49]. The positive predictive value for gestational 
hypertension is 68% [50]. Inclusions of deliveries from 1980-1993 gave up to 14 years 
without morbidity follow-up, but the number of CVD events before 1994 is expected to be 
very low due to the women`s young age. This limitation has been described in details in a 
previous publication [9].  
 
Conclusion  
The association between hypertensive pregnancy disorder and maternal CVD is partially 
explained by established CVD risk factors such as, smoking, elevated BMI, diabetes and 
dyslipidemia, but there remains an increased risk of CVD associated with hypertensive 




pregnancy specific contribution. Even among young women a healthy lifestyle plays an 
important role in prevention of CVD, and targeted follow-up programs should be initiated to 
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Figure title and legends 
Figure 1  
Title: Lifestyle and cardiovascular risk factors and their associations with subsequent maternal 
cardiovascular disease (I00-99) among 20,075 young Norwegian women  
Legend: CONOR indicates Cohort of Norway 1994-2003; HR, age-adjusted hazard ratio (all 
variables except mother`s age at first delivery are adjusted for age at participation in 
CONOR); CI, confidence interval; SBP, systolic blood pressure; DBP, diastolic blood 
pressure; Hypertension defined as SBP ≥140 or DPB ≥90 or currently on antihypertensive 
drugs; MI, myocardial infarction; Glucose; Diabetes, type 1, type 2 or unspecified diagnosed 
before baseline: HDL-C, low high-density lipoprotein cholesterol; Daily smoking, daily 
smoker versus not daily smoker; Alcohol consumption, drinking weekly compared to 
never/seldom; BMI, body mass index (categorical(<25 reference)); Vigorous physical 
activity, less than 1 hour a week versus 1 or more hours a week 
 
Supplementary Figure 1 




Legend: CVD indicates cardiocascular disease; CONOR, Cohort of Norway; SGA, small for 
gestational age; preterm delivery, <37 weeks of gestation; BMI, body mass index; MI, 








Hypertensive pregnancy disorders increase the risk of maternal cardiovascular disease 
after adjustment for cardiovascular risk factors 
 













Table 1 Characteristics of 20,075 Norwegian women with or without a hypertensive pregnancy disorder who subsequently 
participated in Cohort of Norway (CONOR, 1993-2004) 
 No hypertensive pregnancy 
disorder (18,829 (93.8 %)) 
Hypertensive pregnancy disorder   
(1246 (6.2 %)) 
Mother`s age at first delivery, mean (SD) 26.0 (4.6) 26.2 (4.8) 
Infant characteristics   
 Preterm delivery, n (%) 902 (4.8) 196 (15.7)** 
 Small for gestational age, n (%) 2500 (13.3) 316 (25.4)** 
 Stillbirth, n (%) 123 (0.7) 18 (1.4)* 
Parity at baseline, mean (SD) 2.0 (0.8) 2.0 (0.8)* 
Mother`s age at CONOR, mean (SD) 37.2 (6.5) 37.1 (6.7)* 




 Basic education, n (%) 5824 (31.0) 424 (34.1) 
 Secondary education, n (%) 4900 (26.0) 363 (29.1) 
 Tertiary education, n (%)  8105 (43.0) 459 (36.8) 
Marital status   
 Married/cohabitants, n (%) 14,621 (77.7) 993 (79.7) 
 Other, n (%) 4208 (22.3) 253 (20.3) 
Systolic blood pressure, mean (SD) 118.8 (12.6) 127.8 (15.1)** 
Diastolic blood pressure, mean (SD)  70.1 (9.3) 75.9 (10.2)** 
Hypertension §  ** 
 No, n (%) 17,391 (92.4) 936 (75.1) 
 Yes, n (%) 1438 (7.6) 310 (24.9) 




Family history of MI  ** 
 One family member, n (%) 2294 (12.2) 174 (14.0) 
 Two or more family members, n (%) 148 (0.8) 13 (1.0) 
Glucose, n (%) 5.0 (0.9) 5.2 (1.5)** 
Diabetes mellitus †, n (%) 160 (0.9) 30 (2.4)** 
Elevated total cholesterol (> 5.0 mmol/L), n (%) 9839 (53.3) 719 (57.7)** 
Low HDL (< 1.3 mmol/L), n (%)  6688 (35.5) 535 (43.0)** 
Elevated triglycerides (≥ 1.7 mmol/L) ‡, n (%) 3165 (16.8) 329 (26.4)** 
Current daily smoking  ** 
 No, n (%)   12,909 (68.6) 942 (75.6) 
 Yes, n (%) 5920 (31.4) 304 (24.4) 




 Never/seldom, n (%) 5916 (31.4) 452 (36.3) 
 Monthly, n (%) 7549 (40.1) 526 (42.2) 
 Weekly, n (%) 4479 23.8) 209 (16.8) 
 Missing, n (%)  885 (4.7) 59 (4.7) 
BMI units (kg/m2)  ** 
 < 25.0, n (%) 11,671 (62.0) 515 (41.3) 
 25.0-29.9, n (%) 5282 (28.1) 441 (35.4) 
 ≥30.0, n (%) 1876 (10.0) 290 (23.3) 
Vigorous physical activity   
 Less than 1 hour peer week, n (%) 10,821 (57.5) 711 (57.1) 
 1 or more hours per week, n (%) 6390 (33.9) 415 (33.3) 




Hypertensive pregnancy disorders indicate gestational hypertension or preeclampsia; preterm delivery, <37 weeks of gestation; small 
for gestational age, <10th percentile; stillbirth, ≥20 weeks of gestation. 
*indicates P <0.05 and **indicates P <0.001 for comparisons of women with and without hypertensive pregnancy disorder. Chi-square 
test for categorical data and t-test for continuous data. 
† Diabetes mellitus (defined as type 1, type 2, or unspecified) diagnosed before the first pregnancy and/or in CONOR. 
‡ A non-fasting blood sample was collected for serum lipid and glucose analyses. 













Table 2 Risk of cardiovascular disease according to hypertensive disorder (HPD) in first pregnancy (1980-2009) among 20,075 
Norwegian women 
 No./Events Unadjusted 
 HR (95% CI) 
Model A 
HR (95% CI)* 
Model B 
 HR (95% CI)† 
Total CVD     
No HPD‡ 18,829/840 1 (ref.) 1 (ref.) 1 (ref.) 
HPD 1246/125 2.3 (1.9-2.8) 2.3 (1.9-2.7) 1.5 (1.2-1.8) 
 Preeclampsia 884/83 2.1 (1.7-2.7) 2.2 (1.7-2.7) 1.5 (1.2-1.9) 
 Gestational hypertension 362/42 2.7 (2.0-3.6) 2.5 (1.8-3.4) 1.5 (1.1-2.0) 
      
AMI/acute cerebral stroke      

















CVD indicates cardiovascular disease; AMI, acute myocardial infarction; CHD, coronary heart disease; HPD, hypertensive pregnancy 
disorder; HR, hazard ratio; CI, confidence interval. 
* Adjusted for non-modifiable risk factors: age at baseline (yrs.), age at first delivery (yrs.), education (primary, high 
school/vocational, any college/university) and a family history of MI prior to age 60. 
HPD 1246/19 2.2 (1.4-3.6) 2.2 (1.4-3.6) 1.8 (1.1-2.9) 
 Preeclampsia 884/13 2.2 (1.2-3.8) 2.2 (1.3-3.9) 1.8 (1.0-3.3) 
 Gestational hypertension 362/6 2.4 (1.1-5.5) 2.2 (1.0-5.1) 1.8 (0.8-4.1) 
      
CHD     
No  HPD ‡ 18,829/116 1 (ref.) 1 (ref.) 1 (ref.) 
HPD 1246/16 2.2 (1.2-3.5) 1.9 (1.1-3.2) 1.5 (0.9-2.6) 
 Preeclampsia 884/10 1.8 (1.0-3.5) 1.8 (0.9-3.4) 1.4 (0.7-2.7) 




† Adjusted for non-modifiable and modifiable risk factors: age at baseline (yrs.), age at first delivery (yrs.), education (primary, high 
school/vocational, any college/university), hypertension (systolic blood pressure ≥140 or diastolic blood pressure ≥90 or currently on 
antihypertensive drugs), total serum cholesterol (mmol/L), low high-density lipoprotein cholesterol (<1.3 mmol/L), triglycerides 
(mmol/L), daily smoking, body mass index (kg/m2), diabetes mellitus and family history of MI prior to age 60.  













Table 3 Comparison of two different risk prediction models for 10-year risk of cardiovascular disease 
 
CVD indicates cardiovascular disease; HR, hazard ratio; CI, confidence interval; AIC, Akaike information criteria: BIC, Bayesian 
information criteria; NRI, net reclassification improvement; IDI, integrated discrimination improvement. 
*The Harrell`s C statistics were obtained by use of the “somersd” package in STATA 15. Only women with the possibility of at least 
10 years of follow-up were included (n=12,389). 
†Prediction model 1 includes age at baseline (yrs.), age at first delivery (yrs.), educational level (primary, high school/vocational, any 
college/university), hypertension (systolic blood pressure ≥140 or diastolic blood pressure ≥90 or currently on antihypertensive drugs), 
total serum cholesterol (mmol/L), low high-density lipoprotein cholesterol (<1.3 mmol/L), triglycerides (mmol/L), daily smoking, 
body mass index (kg/m2), diabetes mellitus and family history of MI prior to age 60. 
‡ Prediction model 2 includes the variables in prediction model 1 in addition to hypertensive pregnancy disorder (preeclampsia, 
gestational hypertension).  
§Result of continuous NRI and IDI using the “survIDINRI” package in R. 
Total CVD C Statistics* 95% CI P -value AIC BIC NRI (p-value)§ IDI (p-value)§ 
Prediction model 1† 0.69 0.67-0.72 < 0.001 12445.68 12527.35   
Prediction model 2‡ 0.70 0.68-0.72 < 0.001 12436.25 12525.35 0.055 (0.066) 0.001 (0.133) 
